Astellas Pharma Inc.
ALPMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $1,912,323,000 | $1,603,672,000 | $1,518,619,000 | $1,296,163,000 |
| % Growth | 19.2% | 5.6% | 17.2% | – |
| Cost of Goods Sold | $349,206,000 | $292,485,000 | $288,353,000 | $253,009,000 |
| Gross Profit | $1,563,117,000 | $1,311,187,000 | $1,230,266,000 | $1,043,154,000 |
| % Margin | 81.7% | 81.8% | 81% | 80.5% |
| R&D Expenses | $327,651,000 | $294,200,000 | $276,128,000 | $246,010,000 |
| G&A Expenses | $843,032,000 | $740,110,000 | $630,272,000 | $548,840,000 |
| SG&A Expenses | $843,032,000 | $740,110,000 | $630,272,000 | $548,840,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $351,395,000 | $251,359,000 | $38,436,000 | $28,283,000 |
| Operating Expenses | $1,522,078,000 | $1,285,669,000 | $944,836,000 | $823,133,000 |
| Operating Income | $41,039,000 | $25,518,000 | $133,029,000 | $220,021,000 |
| % Margin | 2.1% | 1.6% | 8.8% | 17% |
| Other Income/Exp. Net | -$9,802,000 | -$549,000 | -$668,000 | -$63,135,000 |
| Pre-Tax Income | $31,237,000 | $24,969,000 | $132,361,000 | $156,886,000 |
| Tax Expense | -$19,510,000 | $7,924,000 | $33,647,000 | $32,800,000 |
| Net Income | $50,747,000 | $17,045,000 | $98,714,000 | $124,086,000 |
| % Margin | 2.7% | 1.1% | 6.5% | 9.6% |
| EPS | 28.35 | 9.5 | 54.24 | 67.08 |
| % Growth | 198.4% | -82.5% | -19.1% | – |
| EPS Diluted | 28.24 | 9.47 | 54.09 | 67.05 |
| Weighted Avg Shares Out | 1,796,990 | 1,793,277 | 1,820,019 | 1,849,713 |
| Weighted Avg Shares Out Dil | 1,797,159 | 1,799,660 | 1,825,061 | 1,850,602 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,874,000 | $11,455,000 | $8,110,000 | $6,149,000 |
| Interest Expense | $17,677,000 | $12,005,000 | $8,779,000 | $4,949,000 |
| Depreciation & Amortization | $199,132,000 | $157,840,000 | $105,738,000 | $79,684,000 |
| EBITDA | $248,046,000 | $194,814,000 | $337,390,000 | $297,829,000 |
| % Margin | 13% | 12.1% | 22.2% | 23% |